BMRN:NASDAQ
Biomarin Pharmaceutical Inc
$60.41
arrow_downward
-1.64%(-1.01) 1D
$60.02
arrow_downward
-0.65% (-0.39)bedtimeAfter hours
Closed: Nov 20, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
$61.53
High
$62.01
Low
$59.84
Mkt. cap
11.70B
Avg. vol.
2.55M
Volume
6.06M
52-wk high
$70.98
52-wk low
$49.26
EPS
-$0.10
Beta
0.21
Shares outstanding
193.70M
No. of employees
3K
Open
$61.53
High
$62.01
Low
$59.84
Mkt. cap
11.70B
Avg. vol.
2.55M
Volume
6.06M
52-wk high
$70.98
52-wk low
$49.26
EPS
-$0.10
Beta
0.21
Shares outstanding
193.70M
No. of employees
3K
News stories
From web sources and news partners
TradingView
·
2 days ago
BioMarin Pharmaceutical Bets on Amicus Growth as VOXZOGO Competition Concerns Mount
Yahoo Finance
·
2 days ago
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3.22K
FoundedMar 1997
HeadquartersSan Rafael, California, United States
SectorHealth Care
IndustryBiotechnology
Websitebiomarin.com